Aileron Therapeutics(ALRN) - 2024 Q2 - Quarterly Results

Exhibit 99.1 Aileron Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights Announced positive data from Cohort 1 of the ongoing Phase 1b clinical trial of LTI-03 evaluating low dose LTI-03 (2.5 mg BID) in idiopathic pulmonary fibrosis ("IPF") patients, with positive trends observed in seven of the eight biomarkers evaluated Topline results from Cohort 2 evaluating high-dose LTI-03 (5 mg BID) expected in the third quarter of 2024 AUSTIN, Texas, Aug 14, 2024 (PR NEWSWIRE) – Ailero ...